title: Pseudoangiomatous stromal hyperplasia of the breast.
abstract: Pseudoangiomatous stromal hyperplasia is a relatively common lesion of the breast. In general, it is less commonly found as a clinically palpable mass and is more commonly found as incidental microscopic foci. It is a benign proliferative, probably neoplastic, hormonally driven process of the mammary stromal myofibroblasts. The clinical, radiologic, and cytologic findings can resemble those of fibroadenoma. Histologically, it can be confused with low-grade angiosarcoma. The exact etiology of pseudoangiomatous stromal hyperplasia is still controversial, but a neoplastic process of the stromal myofibroblasts, with a hormonal stimulus in its development and progression, is the favored theory. Most lesions can be cured by complete surgical excision, and patients undergoing the excision have a good prognosis.
authors: Histopathology Department, Dubai Hospital, PO Box 7272, Dubai, United Arab Emirates. badraah009@yahoo.com
authors: Badr
authors: B
authors: AbdullGaffar
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D001941:Breast Diseases / Q000000981:diagnostic imaging / Q000473:pathology* / Q000628:therapy; D003937:Diagnosis, Differential; D005260:Female; D005347:Fibroblasts / Q000648:ultrastructure; D006394:Hemangiosarcoma / Q000175:diagnosis; D006801:Humans; D006965:Hyperplasia / Q000473:pathology; D008297:Male; D008327:Mammography; D008408:Mastectomy; D011379:Prognosis; D017154:Stromal Cells / Q000648:ultrastructure; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D015415:Biomarkers; D013629:Tamoxifen